Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 978 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin (glucophage) Clear all
Terminated Phase 1 Interventional

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

NCT01529593
View directory record Official record
Conditions
Advanced Cancers
Interventions
Temsirolimus, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

NCT01681693
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Metformin on Low Back Pain

NCT04055012
View directory record Official record
Conditions
Low Back Pain
Interventions
Metformin, Placebo
Drug
Lead sponsor
Gwendolyn Sowa
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

NCT04209075
View directory record Official record
Conditions
Diabetes
Interventions
Biomebliss, Metformin, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Not listed No phase listed Observational

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

NCT03627039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

NCT07222098
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Metformin, Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Active, not recruiting Phase 4 Interventional

Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency

NCT05317806
View directory record Official record
Conditions
Plasminogen Activator Inhibitor-1 Deficiency, Cardiac Fibrosis
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
Indiana Hemophilia &Thrombosis Center, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379
View directory record Official record
Conditions
Depression, Insulin Resistance, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions

NCT00778466
View directory record Official record
Conditions
Healthy
Interventions
metformin hydrochloride 1000 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 3, 2026, 10:49 PM EDT
Not yet recruiting Phase 3 Interventional

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

NCT07520110
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Early Phase 1 Interventional Results available

Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer

NCT03109873
View directory record Official record
Conditions
Larynx, Lip, Oral Cavity, Pharynx
Interventions
External Beam Radiation Therapy, Metformin Hydrochloride, Placebo
Radiation · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

NCT00683657
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

NCT01167881
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Glimepiride, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT00279045
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, glyburide, metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
4,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
178
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 3, 2026, 10:49 PM EDT